Newsfeeds - Spark Newswire

3 minute read

BeiGene Announces Results From Phase 3 ALPINE Trial On BRUKINSA; Says ‘in this final response analysis, BRUKINSA met the primary endpoint of superiority over ibrutinib in ORR as determined by IRC’

Today, 6:14 PM

Final Response Analysis from Global Phase 3 ALPINE Trial Provides Additional Support for Potential Use of BRUKINSA in Relapsed or Refractory CLL/SLL BRUKINSA Safety Results Consistent with ALPINE Interim

BGNE

3 minute read

BeiGene Reports Will Present Clinical Results, Biomarker Data On Tislelizumab In Solid Tumors At American Association For Cancer Research Meeting

By Benzinga Newsdesk

Today, 6:14 PM

Results from subanalyses of RATIONALE-303 and -304 add to the growing body of data on tislelizumab as a potential treatment for non-small cell lung cancer Biomarker studies shed light on patient characteristics driving

BGNE

1 minute read

Analyst Ratings

Analyst Ratings For BeiGene

By Benzinga Insights

Today, 6:14 PM

Over the past 3 months, 4 analysts have published their opinion on BeiGene (NASDAQ:BGNE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

BGNE

1 minute read

SVB Leerink Downgrades BeiGene to Market Perform, Lowers Price Target to $177

By Benzinga Newsdesk

Today, 6:14 PM

SVB Leerink analyst Andrew Berens downgrades BeiGene (NASDAQ:BGNE) from Outperform to Market Perform and lowers the price target from $300 to $177.

BGNE

4 minute read

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings

By Shanthi Rexaline

Today, 6:14 PM

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.

ACIU

2 minute read

What’s Going On With Zai Lab, Hutchmed, BeiGene Shares Today

By Vandana Singh

Today, 6:14 PM

Three of the most major drugmakers with roots in China, Zai Lab Ltd (NASDAQ: ZLAB), BeiGene Ltd (NASDAQ: BGNE), and Hutchmed China Ltd (NASDAQ:

BGNE

1 minute read

Chinese Stocks Are Falling: What’s Going On?

By Adam Eckert

Today, 6:14 PM

Shares of multiple Chinese companies are trading lower Thursday following reports the U.S. Securities and Exchange Commision has identified multiple US-listed ADRs as having not adhered to the Holding Foreign Companies Accountable act (HFCAA).

ACMR

10 minute read

Stocks That Hit 52-Week Lows On Thursday

By Benzinga Insights

Today, 6:14 PM

During Thursday, 166 stocks hit new 52-week lows.

ACMR

4 minute read

Uncategorized

Zai Lab Revenue Triples, As It Struggles To Break Cycle Of Mounting Losses

By The Bamboo Works

Today, 6:14 PM

Key takeaways: Zai Lab reported its revenue grew 194% last year, but its loss also increased by 162% as it spent heavily on R&D and marketing The company hopes heavy R&D spending can reduce its dependence on licensed products by improving its capacity to innovate By Ken Lo

BGNE

32 minute read

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

Today, 6:14 PM

On Monday, 524 stocks hit new 52-week lows.

AAL